Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00041509 | ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST) | PHASE2 | COMPLETED | 343 | — | — | Jan 1, 2002 | May 1, 2003 | May 30, 2017 | - | — |
Incidence of VTE during the 28-day treatment period, including death due to VTE
| Arm | Type | Description |
|---|---|---|
| SB424323, 500 mg BID | EXPERIMENTAL | - |
| SB424323, 125 mg BID | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SB-424323 | DRUG | 500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days |
| Placebo | DRUG | matching placebo, oral, BID for 28 days |
Inclusion Criteria: * Patients scheduled for primary elective unilateral total hip arthroplasty (i.e. first time the hip is being replaced on the operative side). * Patients who have given written informed consent to participate in this study. Exclusion Criteria: * Patients with a contraindicatio...